Suspended

Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis

What is being tested

Ivermectin Pill

Drug

Who is being recruted

Dermatitis+8

+ Dermatitis, Atopic

+ Hypersensitivity

From 18 to 80 Years

+23 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Phase 2

Interventional

Study Start: December 2030

See protocol details

Summary

Principal SponsorStanford University

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: December 1, 2030

Actual date on which the first participant was enrolled.

OBJECTIVES: I. Overall response rate of atopic dermatitis in subjects as assessed using Dermatology Life Quality Index (a 10 question questionnaire used to measure the impact of skin disease on the quality of life of an affected person) SECONDARY OBJECTIVES: I. , Eczema Area and Severity Index (EASI), Total Severity Scoring (TSS) II. Safety assessment after 8 weeks with 4 weeks of oral treatment. III. VAS (Visual Analogue Scale, an instrument for the assessment of pruritus) at baseline through eight weeks. OUTLINE: Patients receiving novel oral agent once a week for 4 weeks in the absence of disease progression or unacceptable toxicity.

Official TitleOpen-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis

NCT03553615

Principal SponsorStanford University

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

DermatitisDermatitis, AtopicHypersensitivityHypersensitivity, ImmediateImmune System DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesSkin DiseasesSkin Diseases, GeneticSkin and Connective Tissue DiseasesSkin Diseases, EczematousGenetic Diseases, Inborn

Criteria

8 inclusion criteria required to participate

Must have at least one lesion of atopic dermatitis (At least 1% Body surface Area).

18 years of age or older.

Must be willing to take oral ivermectin once weekly for 4 weeks and monitor over 8 weeks.

For women of child bearing potential, a negative urine pregnancy test

Show More Criteria

15 exclusion criteria prevent from participating

Is currently participating or has participated in another interventional clinical study in the past 2 weeks;

Is age <18 years old.

Has had known or previous hypersensitivity or allergic reactions to oral ivermectin before;

Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus rheumatoid arthritis) which could place the subject at risk or interfere with the accuracy of the study results;

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group

Treatment Groups

Group I

Experimental

12mg oral ivermectin treatment taken once a week for four weeks

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Stanford Hospital and Clinics

Stanford, United StatesOpen Stanford Hospital and Clinics in Google Maps

SuspendedOne Study Center